Clarithromycin-Susceptible and -ResistantHelicobacter pylori Isolates with Identical Randomly Amplified Polymorphic DNA-PCR Genotypes Cultured from Single Gastric Biopsy Specimens Prior to Antibiotic Therapy

Helicobacter pyloriinfection has been established as an etiologic factor in nonautoimmune gastritis, peptic ulcer disease (PUD), gastric carcinoma, and lymphoma (1, 3, 10). Since curing H. pylori infection prevents peptic ulcer recurrence, the eradication of the organism has become the cornerstone in the treatment of PUD (15). Clarithromycin (CLR) in combination with metronidazole (MTZ) is often used in H. pylori eradication regimens (4).H. pylori resistance to these drugs substantially reduces the success rate of CLR-plus-MTZ eradication regimens (4). The 23S rRNA gene is present in two copies in the H. pylorigenome (12, 13). In H. pylori, seven different point mutations (A2115→G, G2141→A, A2142→G, A2142→C, A2143→G, A2143→C, and A2142→T) in the peptidyltransferase region of the V domain of the 23S rRNA gene have been found to be associated with resistance to CLR (5, 9, 11, 12, 18). In a recent study, it was found that among CLR resistant H. pylori, the predominant mutations were A2143→G and A2142→G, while virtually all CLR-susceptible H. pylori had no mutation in their 23S rRNAs (17).

It has been reported that the H. pylori population in a patient can be heterogeneous with respect to MTZ susceptibility (20). Infection by a mixed population of CLR-susceptible and CLR-resistant H. pylori has been reported (6, 7, 8, 16). However, in most of these studies (6, 7, 16), discrimination between mixed H. pylori infection and infection with H. pylori heterozygous for 23S rRNA was not established. The aim of this study was to evaluate the relevance of heterogeneity in susceptibility to CLR in H. pyloripopulations from patients with gastritis or PUD prior to anti-H. pylori treatment. In this study, a distinction was made between mixed H. pylori infection and infection with H. pylori heterozygous for 23S rRNA.

H. pylori isolates were cultured from gastric biopsy specimens from 976 patients from the Amsterdam area who were referred for upper gastrointestinal tract endoscopies in 1997 and 1998 because of dyspeptic symptoms (14). Briefly, each specimen was smeared on Columbia agar (Oxoid CM 331; Unipath Ltd., Basingstoke, England) plates containing 7% (vol/vol) horse blood. Colonies that exhibited the characteristic morphology were identified as H. pylori if they were urease, catalase, and oxidase positive. The cultures of the antrum and corpus were collected separately with swabs, which were subsequently shaken in 8% glycerol-peptone. These bacterial suspensions were stored at −70°C. CLR susceptibilities were determined by the E-test (AB Biodisk, Solna, Sweden) according to the instructions of the manufacturer (20). Colonies growing within the zone of growth inhibition of the bacterial lawn were subcultured on blood agar for 3 days before assessment of the CLR MIC was performed. Isolates were considered resistant to CLR if the MIC was ≥2 mg of CLR/liter (7). Mutations in the 23S rRNA gene were assessed by a PCR-based reverse hybridization onto a line probe assay (INNO-LiPA) (16). This LiPA allows the simultaneous detection of all of the aforementioned point mutations in the 23S rRNA gene associated with CLR resistance. In addition, the genotype of eachH. pylori strain was assessed by randomly amplified polymorphic DNA (RAPD)-PCR using four different primers (14). For analysis, the four profiles were combined.

Among the 976 H. pylori populations cultured, 51 (5.2%) were resistant to CLR. Close examination of the E-test plates revealed that six (12%) of these 51 H. pylori populations were heterogeneous regarding CLR susceptibility. In these H. pylori populations, the majority of bacteria were susceptible to CLR, but Helicobacter colonies were also growing within the zones of growth inhibition of the bacterial lawn. For each heterogeneous H. pylori population, the MICs of CLR for two resistant H. pylori colonies and for two susceptibleH. pylori colonies were reassessed by E-test, and the DNAs of the colonies were subjected to the 23S ribosomal DNA (rDNA) LiPA (Fig. 1; Table 1). In all heterogeneousH. pylori populations, the MICs of CLR for the two CLR-resistant colonies were high, and the colonies harbored identical 23S rDNA mutations in both copies of rRNA operons, associated with CLR resistance. The MICs for all susceptible H. pylori colonies were low, and the colonies had wild-type 23S rDNA. RAPD-PCR profiles of the resistant and susceptible H. pylori colonies of each of the heterogeneous H. pylori populations were identical, indicating identical genotypes (Fig. 2).

• Open in new tab
• Download powerpoint

Fig. 1.

LiPA results for clarithromycin-resistant H. pylori isolates from six patients. The results from one of the clarithromycin-resistant H. pylori colonies from the heterogeneous H. pylori population of each of the six patients are presented here. WT, wild type.

• Open in new tab
• Download powerpoint

Fig. 2.

RAPD profiles of CLR-resistant and -susceptible H. pylori isolates from single biopsy specimens. Two CLR-susceptible (S) and two CLR-resistant (R) colonies from the heterogeneousH. pylori populations of six patients were assessed by RAPD-PCR. m, 100-bp molecular size markers.

Our results are in accordance with the results from recent studies by Maeda and coworkers (6), Matsuoka and colleagues (8), and van Doom and collaborators (16) reporting mixed infections with CLR-susceptible and CLR-resistantH. pylori. However, genotyping was not performed in those studies. In addition, in another study, the susceptibility of H. pylori to CLR was assessed by molecular biological techniques directly on biopsy specimens from H. pylori-infected patients (7). Seventeen percent of the H. pylori-positive biopsy specimens yielded 23S rDNA PCR products that hybridyzed with both the wild-type probe and one of the mutant probes. The results were explained by either mixed infection with resistant and susceptible H. pylori or infection by H. pylori heterozygous for the 23S rRNA gene. Our findings favor the first explanation.

Only a limited number of different 23S rDNA point mutations were found among the heterogeneous H. pylori populations. The CLR-resistant H. pylori isolates of four of the six heterogeneous H. pylori populations had the A2142→G point mutation, one had the A2143→G mutation, and another had the A2142→C mutation in their 23S rRNA genes. Possibly, in an environment without CLR, the disadvantage of these point mutations in the 23S rRNA gene inH. pylori is insignificant, resulting in a lack of negative selection of these 23S rRNA mutants. This is supported by the results of in vitro experiments (2, 19). In these experiments, it was found that the growth rates of H. pylori isolates with the A2142→G, A2142→C, or A2143→G mutation did not differ from that of the wild type, but H. pylori isolates with other 23S rDNA mutations grew more slowly (2). In addition, Wang and coworkers showed identical growth rates of wild-typeH. pylori and H. pylori with the A2142→G or A2143→G 23S rDNA mutation (19). From the individual growth rates and the patterns of competitive growth, it was concluded that the order of preference of competitive accumulation is A2142→G > A 2143→G >>> A2142→C > A2143→C (A2143→T). The prevalence of the A2142→G, A2143→G, and A2142→C mutations among the heterogeneous H. pyloripopulations in our study is consistent with this order.

In conclusion, the results show coexistence of CLR-resistant and -susceptible H. pylori isolates with identical genotypes in patients prior to treatment. If only a single colony from the primaryH. pylori populations is used to test for CLR susceptibility, the results can be misinterpreted. Assessment of 23S rRNA mutations in H. pylori directly from biopsy specimens by molecular biological techniques, such as the LiPA, has the advantage that infection with a mixed H. pylori population is easily detected. In addition, knowledge of the type of 23S rRNA mutation may be important since CLR MICs are associated with the type of 23S rRNA mutation in H. pylori (17).

• Copyright © 2001 American Society for Microbiology